Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes

Novo Nordisk

Status and phase: Completed; Phase 3

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: insulin detemir; Drug: insulin aspart; Drug: insulin glargine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00106366

NN304-2175

Details and patient eligibility

About

This trial is conducted in the United States of America (USA). The purpose of this study is to determine if the use of insulin detemir in combination with insulin aspart is safe and at least as effective as insulin glargine in combination with insulin aspart for the control of blood glucose in patients with Type 2 diabetes.

Enrollment: 389 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Type 2 Diabetes for more than 12 months
• Currently treated with glucose lowering tablets or insulin
• HbA1c: 7.0-12.0%

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)